Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors

NCT05495828 · clinicaltrials.gov ↗

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

B-cell Lymphoma

Interventions

DRUG: Orelabrutinib

Sponsor

Peking University People's Hospital